Bayer Receives FDA Approval for Stivarga ® (regorafenib) for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)

Stivarga is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients previously treated with Nexavar ® (sorafenib) / First new treatment for HCC in a decade / Pivotal Phase III RESORCE trial defines a new treatment plan in HCC which involves use of Stivarga directly after progression on Nexavar
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news